Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Contrave Launch Raises Hopes For Korean Obesity Market Growth

This article was originally published in PharmAsia News

Executive Summary

Following the successful debut of Arena's Belviq in 2015, Orexigen's Contrave, which will be released in South Korea in the second quarter through its partner Kwang Dong Pharm, is set to boost the domestic obesity treatment market which had been depressed since the country banned sales of sibutramine-based drugs in 2010.

Advertisement

Related Content

Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register